VITRUVIAE is a preclinical stage biotechnology company focused on developing immunotherapies that target Man 9 (a sugar) and PS (a lipid) as a new strategy to treat cancer. Currently known antitumor therapeutic antigens are expressed in normal tissues and their targeting causes toxicity, low therapeutic index, and sub-curative dosing. Further, protein antigen loss accounts for about a third of all T cell engaging and CAR-T failures. Antigen down-regulation and treatment-related toxicities are associated with a low therapeutic index and account for the remaining treatment failures. VIT-GLT3 is a trispecific, immune cell engaging immunotherapy that targets tumor specific, non-mutating, Man9 and PS. Our technology is being developed to treat pediatric acute myeloid leukemia, a rare and particularly difficult to treat pediatric cancer with a 50% relapse and for which innovative treatments are sorely needed.
Website: https://www.vitruviae.com